Medtronic Inc MDT

$88.51 -0.79 (-0.88%)

Valuation

Market cap
116,107,352,000
Revenue TTM
$36,364,000,000
Net income TTM
$4,800,000,000
PE ratio
16.04
Forward PE
15.37
Profit margin
13.20%
Debt to equity
0.55

Trading

Volume
10,964,806
Avg volume
8,004,414
Day's range
$88.46 – $90.28
Shares out
1,279,138,000
Stochastic %K
11%
Beta
0.56
Analysts
Strong Sell
Price target
$103.72

Price

Company profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, an...

Show more

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Industry
Medical Devices
Sector
Healthcare
Phone
353 1 438 1700
Website
https://www.medtronic.com
Address
Building Two, Parkmore Business Park West, Galway, Ireland

Latest news

Stocktwits

Orbit100 Sep 24, 7:59 PM
$MDT Now is the time to double down medtroic. Jim Cramer's description of Medtronic as a quandary likely reflects that, despite improved results, the stock is still down 30% from its 2021 high. Its price-to-sales and price-to-earnings ratios are both below their five-year averages. Even after reporting strong fiscal first-quarter 2027 results, including nearly 14% revenue growth and a guidance raise after just a single quarter, Wall Street seems to still be stuck in a "show me" mood. That said, it looks like the company is already showing that it has turned a corner, but investors are not giving it any credit for the improvement. If you are a dividend lover, you might want to get to know Medtronic now, before Wall Street changes its mind. While investors can be poor judges of value over short periods, they tend to get things right over long periods. Taking advantage of "quandaries" like Medtronic can both increase the income you generate and lead to attractive long-term capital growth
0 replies
inelegantinvest Sep 24, 10:06 AM
$MDT $MMED Medtronic’s MiniMed exchange offer includes an odd-lot exemption: holders of fewer than 100 MDT shares who tender ALL their shares are exempt from proration. The offer targets about $107.53 of MMED for each $100 of MDT, but the 4.5939-share cap can reduce that spread. At Sep. 23 prices, our 99-share paper trade implies roughly a 5.7% gross spread if the cap binds. Full mechanics + risks: https://www.inelegantinvestor.com/2026/09/24/medtronic-minimed-odd-lot-exchange-offer/
0 replies
Big_Joe96 Sep 23, 11:00 PM
$MDT they tryin to fake me out again. Just picked up an extra 50 shares here for the long
0 replies
jim22u Sep 23, 5:43 PM
$MDT Horrible losses. Higher interest rates or something else? Other stocks in the same sector not hit nearly as much. Getting ready to sell, so you can expect a big gain tomorrow.
0 replies
NVDAMillionaire Sep 22, 7:35 PM
$MDT Great piece that accurately captures MDT's current position. So if you want to refresh your understanding of MDT or learn about MDT for the first time, this is essential reading. https://everyticker.com/quote/MDT/analysis/medtronic-s-strategic-metamorphosis-diabetes-spin-off-and-pfa-dominance-drive-margin-inflection-nyse-mdt
0 replies
jim22u Sep 22, 6:43 PM
$MDT Don't understand why it is going down the last 5 trading days. The other companies in the sector are going up. Positive news flow. It was close to a golden cross.
1 replies
dustlesspuma Sep 21, 8:12 PM
🟢 $MDT 92.5C Oct 16 💰 $63,800 premium 💵 $2.05/contract 📊 0.9x Vol/OI 📍 Spot $92.04 🚨 Repeat sweep 🌊 Dark Flow | Options Flow
0 replies
Orbit100 Sep 21, 6:06 PM
$MDT Medtronic's bull case say the target price to be no less than $98.
0 replies